Oragenics Says On Sept. 22, Co, Eleszto Genetika, Mutually Terminated Lantibiotic ECC Agreement Dated Mar. 1, 2021, Says Will Cease Pre-Clinical Development Of It's Product Candidate OG716, Other Compounds Covered By Lantibiotic ECC